Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110624 | 0.92 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL14862600 | 0.82 | HDAC1 (0.53) | SMN1; SMN2LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL4112248 | 0.81 | MEN1 (0.48) | SMN1; SMN2LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL13310309 | 0.81 | HDAC1 (0.43) | SMN1; SMN2LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL5923062 | 0.79 | ALDH1A1 (0.54) | SMN1; SMN2LMNAKDM4EKMT2ARAB9A | |
| SCHEMBL5922992 | 0.79 | RAB9A (0.56) | SMN1; SMN2LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL14862212 | 0.78 | ALDH1A1 (0.71) | SMN1; SMN2LMNAKDM4EKMT2AMEN1 | |
| SCHEMBL5923461 | 0.77 | MAPT (0.53) | KMT2AMEN1ALDH1A1TSHRMAPT | |
| SCHEMBL5923162 | 0.76 | L3MBTL1 (0.44) | SMN1; SMN2LMNAKMT2AMEN1RAB9A | |
| SCHEMBL5923157 | 0.76 | L3MBTL1 (0.48) | LMNAKMT2AMEN1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | SMN1; SMN2 1226/4885LMNA 620/4885KDM4E 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.